Drugs / fluorouracil
last change 2 days ago re-read 8 days ago

fluorouracil

Small molecule

Developed for
colorectal cancer · malignant pancreatic neoplasm · gastric cancer · hepatocellular carcinoma · pancreatic adenocarcinoma · esophageal cancer · breast cancer · rectal cancer
+235 more · head and neck cancer · gastroesophageal junction adenocarcinoma · pancreatic ductal adenocarcinoma · head and neck squamous cell carcinoma · gastric adenocarcinoma · metastatic malignant neoplasm · nasopharyngeal carcinoma · esophageal squamous cell carcinoma · biliary tract cancer · esophageal adenocarcinoma · metastasis from malignant tumor of colon · rectum adenocarcinoma · colon carcinoma · cancer of unknown primary site · gastroesophageal cancer · squamous cell carcinoma · colorectal neoplasm · rectal carcinoma · actinic keratosis · gastric neoplasm · gastroesophageal adenocarcinoma · cancer · colorectal carcinoma · non-small cell lung carcinoma · female breast carcinoma · neoplasm · intrahepatic cholangiocarcinoma · metastatic neoplasm · peritoneal carcinomatosis · rectal signet ring cell adenocarcinoma · rectum mucinous adenocarcinoma · cholangiocarcinoma · colorectal adenocarcinoma · carcinoma of esophagus · colon mucinous adenocarcinoma · colon signet ring cell adenocarcinoma · pancreatic exocrine neoplasm · urinary bladder cancer · anal carcinoma · colon adenocarcinoma · digestive system cancer · gallbladder cancer · human papilloma virus infection · malignant colon neoplasm · neoplasm of esophagus · rectal neoplasm · cervical cancer · head and neck neoplasm · lung cancer · neuroendocrine carcinoma · oral cavity squamous cell carcinoma · pancreatic neoplasm · extrahepatic bile duct carcinoma · oropharynx cancer · renal cell carcinoma · adenocarcinoma · anal canal cancer · carcinoid tumor · cervical intraepithelial neoplasia grade 2/3 · gallbladder carcinoma · hepatoblastoma · larynx cancer · liver cancer · lymphoma · oral cavity cancer · ovarian cancer · pancreas disorder · peritoneal neoplasm · small intestine adenocarcinoma · urothelial carcinoma · anal squamous cell carcinoma · basal cell carcinoma · bile duct cancer · carcinoma · colonic neoplasm · cutaneous neuroendocrine carcinoma · endometrial cancer · glaucoma · high grade malignant neoplasm · hilar cholangiocarcinoma · human papillomavirus-related squamous cell carcinoma · hypopharyngeal carcinoma · infiltrating bladder urothelial carcinoma · keloid · kidney cancer · nasopharyngeal neoplasm · neuroendocrine neoplasm · oral cavity neoplasm · pancreatic acinar cell carcinoma · pediatric hepatocellular carcinoma · small intestine cancer · triple-negative breast carcinoma · urethra cancer · vitiligo · adult hepatocellular carcinoma · ampulla of vater adenocarcinoma · ampulla of vater cancer · anal canal carcinoma · anal canal squamous cell carcinoma · anal margin squamous cell carcinoma · anus basaloid carcinoma · anus cancer · appendix cancer · cloacogenic carcinoma · diffuse gastric adenocarcinoma · digestive system carcinoma · fibrolamellar hepatocellular carcinoma · gastric carcinoma · gastric cardia adenocarcinoma · gastric intestinal type adenocarcinoma · hypopharynx cancer · hypopharynx squamous cell carcinoma · laryngeal carcinoma · malignant exocrine pancreas neoplasm · nasal cavity and paranasal sinus neoplasm · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · neoplastic syndrome · oropharynx squamous cell carcinoma · ovarian carcinoma · pancreatic endocrine carcinoma · pancreatic neuroendocrine tumor · peritoneal carcinoma · primary peritoneal carcinoma · proliferative vitreoretinopathy · renal pelvis/ureter urothelial carcinoma · skin neoplasm · skin squamous cell carcinoma · squamous cell intraepithelial neoplasia · acute necrotizing pancreatitis · adenocarcinoma of gallbladder and extrahepatic biliary tract · anus neoplasm · appendiceal neoplasm · appendix carcinoma · atopic eczema · basal cell carcinoma, susceptibility to, 7 · bile duct adenocarcinoma · bladder urachal carcinoma · bone squamous cell carcinoma · breast neoplasm · carcinoma of pharynx · carcinoma of the ampulla of vater · central nervous system cancer · chronic dacryocystitis · colonic disorder · common wart · digestive system disorder · digestive system neoplasm · digestive system neuroendocrine neoplasm · disorder of orbital region · disseminated intravascular coagulation · distal biliary tract carcinoma · dysplasia of cervix · ependymoma · esophageal disorder · exocrine pancreatic carcinoma · extragonadal nonseminomatous germ cell tumor · extragonadal seminoma · extrahepatic bile duct adenocarcinoma · fallopian tube cancer · gastrointestinal stromal tumor · head and neck carcinoma · hepatobiliary neoplasm · hypopigmentation of the skin · intraepithelial neoplasia · Keratocystic odontogenic tumor · keratosis · lacrimal duct obstruction · larynx verrucous carcinoma · lip and oral cavity carcinoma · major salivary gland cancer · malignant testicular germ cell tumor · mesothelioma · metastatic carcinoma in the bone · metastatic malignant neoplasm in the brain · metastatic malignant neoplasm in the colon · metastatic malignant neoplasm in the lymph nodes · mucinous ovarian cancer · nasal cavity and paranasal sinus carcinoma · nasal cavity neoplasm · nasopharyngeal type undifferentiated carcinoma · neoplasm of neck · neoplasm of oropharynx · neoplastic disease or syndrome · nodular basal cell carcinoma · non-Hodgkin lymphoma · oral mucosa leukoplakia · oropharyngeal carcinoma · ovarian germ cell tumor · pancreatic adenosquamous carcinoma · pancreatic intraductal papillary-mucinous neoplasm · paranasal sinus neoplasm · periampullary adenocarcinoma · peritoneum cancer · photosensitivity disease · plantar wart · posterior fossa ependymoma · prostate cancer · prurigo nodularis · psoriasis · pterygium · respiratory system cancer · retinal detachment · salivary gland squamous cell carcinoma · sinonasal undifferentiated carcinoma · skin disorder caused by infection · squamous cell carcinoma of the oral tongue · stomach carcinoma in situ · thymic carcinoma · thyroid gland carcinoma · tongue carcinoma · transitional cell carcinoma · undifferentiated carcinoma of nasopharynx · undifferentiated pancreatic carcinoma · urachus cancer · ureter cancer · urethra transitional cell carcinoma · uterine cervix carcinoma in situ · verrucous carcinoma of oral cavity · Bowen disease of the skin · breast mucinous carcinoma · chalazion · conjunctival pterygium · diffuse gastric cancer · HER2 positive breast carcinoma · hyperpigmentation of the skin · inflammatory breast carcinoma · invasive tubular breast carcinoma · laryngeal squamous cell carcinoma · non-invasive bladder urothelial carcinoma · open-angle glaucoma · portal vein thrombosis · skin squamous cell carcinoma in situ · superficial multifocal basal cell carcinoma · urinary bladder neoplasm
Investigated by
National Cancer Institute (NCI) · Sun Yat-sen University · Fudan University · Sanofi · Alliance for Clinical Trials in Oncology · M.D. Anderson Cancer Center
+858 more · UNICANCER · European Organisation for Research and Treatment of Cancer - EORTC · Federation Francophone de Cancerologie Digestive · GERCOR - Multidisciplinary Oncology Cooperative Group · Memorial Sloan Kettering Cancer Center · SWOG Cancer Research Network · Merck Sharp & Dohme LLC · Bristol-Myers Squibb · Tianjin Medical University Cancer Institute and Hospital · National Taiwan University Hospital · Amgen · Eastern Cooperative Oncology Group · Hoffmann-La Roche · ImmunityBio, Inc. · Pfizer · Dana-Farber Cancer Institute · Genentech, Inc. · Radiation Therapy Oncology Group · Massachusetts General Hospital · Washington University School of Medicine · Fujian Cancer Hospital · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sixth Affiliated Hospital, Sun Yat-sen University · University of Chicago · Zhejiang Cancer Hospital · Jiangsu HengRui Medicine Co., Ltd. · Medical Research Council · Celgene Corporation · Peking University · UNC Lineberger Comprehensive Cancer Center · Brigham and Women's Hospital · Ipsen · NRG Oncology · National Health Research Institutes, Taiwan · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · ECOG-ACRIN Cancer Research Group · Gruppo Oncologico del Nord-Ovest · NSABP Foundation Inc · National Cheng-Kung University Hospital · SCRI Development Innovations, LLC · Seoul National University Hospital · Shanghai Jiao Tong University School of Medicine · AIO-Studien-gGmbH · AstraZeneca · Cancer and Leukemia Group B · Case Comprehensive Cancer Center · Chang Gung Memorial Hospital · China Medical University Hospital · City of Hope Medical Center · NCIC Clinical Trials Group · Peking Union Medical College Hospital · Ruijin Hospital · West China Hospital · Akeso · Asan Medical Center · Eli Lilly and Company · Gustave Roussy, Cancer Campus, Grand Paris · Institut du Cancer de Montpellier - Val d'Aurelle · Scottish Cancer Therapy Network · Taipei Veterans General Hospital, Taiwan · University of California, San Francisco · University of Michigan Rogel Cancer Center · Assistance Publique - Hôpitaux de Paris · Cancer Institute of the State of São Paulo · Cancer Research UK · Centre Hospitalier Universitaire Dijon · Eastern Hepatobiliary Surgery Hospital · First Affiliated Hospital of Zhejiang University · First People's Hospital of Foshan · Fox Chase Cancer Center · Groupe Oncologie Radiotherapie Tete et Cou · H. Lee Moffitt Cancer Center and Research Institute · all 864 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) FLUOROURACIL — 2016-07-29 fda.gov ↗
Approved US (FDA) FLUOROURACIL — 1962-04-25 fda.gov ↗

Trials 1,500 · started per year

today
US approved 1962
1
1
1
1
2
4
2
4
10
5
6
14
25
26
39
37
30
40
38
37
42
41
57
37
43
39
43
46
39
39
46
55
54
61
48
60
68
63
57
83
85
64
196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 017 trials
Phase 0 NCT07254091 Jan 2026 → Jan 2027 expected malignant pancreatic neoplasm Northwell Health Recruiting No outcome recorded
Phase 0 NCT07531056 Dec 2025 → Sep 2026 overdue keloid Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan Recruiting No outcome recorded
Phase 0 NCT07398807 Aug 2025 → Feb 2026 overdue vitiligo Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan Recruiting No outcome recorded
Phase 0 NCT07034742 Jun 2025 → Jan 2026 overdue gastric adenocarcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 0 NCT06062602 Jul 2021 → Nov 2022 head and neck squamous cell carcinoma Presage Biosciences Completed No outcome recorded
Phase 0 NCT05007587 Jul 2021 → Jun 2022 hepatocellular carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 0 NCT04839731 Apr 2021 → Dec 2023 skin squamous cell carcinoma Carilion Clinic Unknown No outcome recorded
Phase 0 NCT03196180 Oct 2019 → Nov 2020 cervical intraepithelial neoplasia grade 2/3, uterine cervix carcinoma in situ National Cancer Institute (NCI) Completed No outcome recorded
Phase 0 NCT03970252 Jul 2019 → May 2024 pancreatic ductal adenocarcinoma Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 0 NCT03996252 Jul 2019 → Jan 2020 actinic keratosis Tulane University Terminated No outcome recorded
Phase 1122 trials · 2 met primary
Phase 1 NCT07363408 Dec 2026 → Jul 2027 expected colorectal carcinoma City of Hope Medical Center Not yet recruiting No outcome recorded
Phase 1 NCT07829185 Dec 2026 → Dec 2029 expected pancreatic ductal adenocarcinoma University of Oklahoma Not yet recruiting No outcome recorded
Phase 1 NCT07859085 Oct 2026 → Mar 2029 expected colorectal neoplasm, pancreatic ductal adenocarcinoma Genentech, Inc. Not yet recruiting No outcome recorded
Phase 1 NCT07060014 Sep 2026 → Sep 2028 expected appendix cancer, small intestine cancer The Methodist Hospital Research Institute Recruiting No outcome recorded
Phase 1 NCT07794059 Sep 2026 → Sep 2027 expected actinic keratosis Cedars-Sinai Medical Center Not yet recruiting No outcome recorded
Phase 1 NCT07649655 Jul 2026 → Mar 2028 expected colorectal cancer Shanghai EpimAb Biotherapeutics Co., Ltd. Not yet recruiting No outcome recorded
Phase 1 NCT06362226 Jun 2026 disorder of orbital region Virginia Commonwealth University Withdrawn No outcome recorded
Phase 1 NCT05296005 Dec 2025 gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Ohio State University Comprehensive Cancer Center Withdrawn No outcome recorded
Phase 1 NCT07030283 Dec 2025 → Jul 2028 expected pancreatic ductal adenocarcinoma University of Colorado, Denver Recruiting No outcome recorded
Phase 1 NCT07059299 Dec 2025 → Aug 2027 expected esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Recruiting No outcome recorded
Show all 122 trials opens the full record — a long page
Phase 1/2104 trials · 1 met primary · 3 missed
Phase 1/2 NCT07848568 Dec 2026 → Jun 2037 expected posterior fossa ependymoma Children's Oncology Group Not yet recruiting No outcome recorded
Phase 1/2 NCT07863869 Sep 2026 → May 2029 expected colorectal cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1/2 NCT07805551 Aug 2026 → Aug 2030 expected colorectal cancer Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07522411 Apr 2026 → Dec 2027 expected hepatocellular carcinoma BinYong Liang Not yet recruiting No outcome recorded
Phase 1/2 NCT07595172 Apr 2026 → Aug 2028 expected pancreatic ductal adenocarcinoma West China Hospital Recruiting No outcome recorded
Phase 1/2 NCT07282184 Oct 2025 → Jun 2027 expected hepatocellular carcinoma Tongji Hospital Recruiting No outcome recorded
Phase 1/2 NCT07256782 Oct 2025 → Oct 2026 expected neoplastic disease or syndrome Qilu Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07312422 Sep 2025 → Apr 2026 overdue malignant pancreatic neoplasm Zhejiang Provincial People's Hospital Recruiting No outcome recorded
Phase 1/2 NCT07197827 Sep 2025 → Sep 2028 expected neoplasm MediLink Therapeutics (Suzhou) Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06943820 May 2025 → Dec 2026 expected colorectal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma Akeso Recruiting No outcome recorded
Phase 2803 trials · 25 met primary · 35 missed
Phase 2 NCT06890624 Oct 2026 → Oct 2029 expected malignant colon neoplasm Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07844057 Oct 2026 → Oct 2029 expected chemotherapy-induced toxicity, metastatic malignant neoplasm, small intestine adenocarcinoma Annika Kurreck Not yet recruiting No outcome recorded
Phase 2 NCT07802418 Oct 2026 → Jun 2031 expected malignant pancreatic neoplasm Herlev Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07814417 Oct 2026 → Nov 2028 expected colorectal neoplasm Eli Lilly and Company Not yet recruiting No outcome recorded
Phase 2 NCT07817888 Sep 2026 → Sep 2028 expected — Sixth Affiliated Hospital, Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07815288 Sep 2026 → Dec 2029 expected colorectal adenocarcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2 NCT07827053 Sep 2026 → Sep 2029 expected pancreatic ductal adenocarcinoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Not yet recruiting No outcome recorded
Phase 2 NCT07833241 Sep 2026 → Sep 2028 expected pancreatic exocrine neoplasm Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07603375 Sep 2026 → Aug 2029 expected esophageal adenocarcinoma Duke University Recruiting No outcome recorded
Phase 2 NCT07810114 Aug 2026 → Dec 2027 expected rectal cancer Fudan University Not yet recruiting No outcome recorded
Show all 803 trials opens the full record — a long page
Phase 2/342 trials · 5 met primary · 9 missed
Phase 2/3 NCT07554456 Jun 2026 → Dec 2028 expected esophageal squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2/3 NCT07251062 Dec 2025 → Dec 2029 expected esophageal squamous cell carcinoma CSPC Megalith Biopharmaceutical Co.,Ltd. Not yet recruiting No outcome recorded
Phase 2/3 NCT06958419 May 2025 → Dec 2030 expected colorectal cancer Sixth Affiliated Hospital, Sun Yat-sen University Recruiting No outcome recorded
Phase 2/3 NCT06028737 Mar 2025 → Apr 2027 expected gastric adenocarcinoma, gastroesophageal cancer, gastroesophageal junction adenocarcinoma Ukrainian Society of Clinical Oncology Recruiting No outcome recorded
Phase 2/3 NCT06758830 Jan 2025 → Dec 2029 expected rectal cancer National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos Recruiting No outcome recorded
Phase 2/3 NCT06441565 May 2024 → Dec 2025 overdue colorectal cancer Sun Yat-sen University Recruiting No outcome recorded
Phase 2/3 NCT06241599 Feb 2024 → Feb 2026 overdue nasopharyngeal carcinoma Sun Yat-sen University Recruiting No outcome recorded
Phase 2/3 NCT06279130 Jan 2024 → Jan 2029 expected — The Netherlands Cancer Institute Recruiting No outcome recorded
Phase 2/3 NCT05610163 Dec 2022 → Jul 2030 expected rectum adenocarcinoma Alliance for Clinical Trials in Oncology Active not recruiting No outcome recorded
Phase 2/3 NCT05171166 Dec 2021 → Oct 2025 hepatocellular carcinoma Peking University Terminated No outcome recorded Stop: Enrollment
Phase 3310 trials · 36 met primary · 49 missed
Phase 3 NCT07689539 Sep 2026 → Jul 2028 expected malignant pancreatic neoplasm Jiangxi Kvvit Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06783491 May 2026 → Jun 2030 expected colorectal carcinoma Maimónides Biomedical Research Institute of Córdoba Recruiting No outcome recorded
Phase 3 NCT06197425 May 2026 → May 2032 expected colorectal adenocarcinoma Centre Hospitalier Universitaire Dijon Recruiting No outcome recorded
Phase 3 NCT07340567 May 2026 → Nov 2032 expected colorectal cancer UNICANCER Not yet recruiting No outcome recorded
Phase 3 NCT07472868 Mar 2026 → Mar 2030 expected rectal carcinoma J. W. A. Burger Not yet recruiting No outcome recorded
Phase 3 NCT07004413 Jan 2026 → Jan 2028 expected colorectal cancer Charite University, Berlin, Germany Not yet recruiting No outcome recorded
Phase 3 NCT07277842 Dec 2025 → Dec 2028 expected rectum adenocarcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07118800 Dec 2025 → Dec 2030 expected rectum adenocarcinoma UNICANCER Not yet recruiting No outcome recorded
Phase 3 NCT06346197 Dec 2025 → May 2028 expected gastric cancer, metastatic malignant neoplasm Centre Leon Berard Recruiting No outcome recorded
Phase 3 NCT07238283 Dec 2025 → Oct 2028 expected — Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Show all 310 trials opens the full record — a long page
Phase 433 trials · 1 met primary · 1 missed
Phase 4 NCT07801027 Nov 2026 → Jan 2030 expected biliary tract cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, uterine cervix neoplasm Merck Sharp & Dohme LLC Not yet recruiting No outcome recorded
Phase 4 NCT07352566 Aug 2026 → Jun 2030 expected atopic eczema, psoriasis University of California, San Francisco Not yet recruiting No outcome recorded
Phase 4 NCT07790445 Jul 2026 → Dec 2028 expected biliary tract cancer Zhai Wenlong Recruiting No outcome recorded
Phase 4 NCT07446465 Mar 2026 → Jan 2027 expected colorectal cancer Ye Xu Not yet recruiting No outcome recorded
Phase 4 NCT07158164 Aug 2025 → Jul 2027 expected breast neoplasm, colorectal neoplasm, head and neck neoplasm, intraepithelial neoplasia Rutgers, The State University of New Jersey Recruiting No outcome recorded
Phase 4 NCT07397520 Aug → Nov 2025 — Instituto de Oftalmología Fundación Conde de Valenciana Completed No outcome recorded
Phase 4 NCT07014540 Jun 2025 → Dec 2026 expected neuroendocrine carcinoma Beijing GoBroad Hospital Not yet recruiting No outcome recorded
Phase 4 NCT06461442 Jul 2024 → Sep 2026 overdue actinic keratosis University of California, Davis Enrolling by invitation No outcome recorded
Phase 4 NCT06311916 May 2024 → Dec 2027 expected hepatocellular carcinoma Chen Xiaoping Not yet recruiting No outcome recorded
Phase 4 NCT06311942 Apr 2024 → Dec 2027 expected hepatocellular carcinoma Chen Xiaoping Recruiting No outcome recorded
Phase not applicable67 trials · 2 met primary · 4 missed
— NCT07837908 Aug 2026 → Jul 2027 expected hypopigmentation of the skin Al-Azhar University Not yet recruiting No outcome recorded
— NCT07618546 May 2026 → Mar 2027 expected hepatocellular carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
— NCT07283939 Feb 2026 → May 2030 expected appendix carcinoma, cancer of unknown primary site, carcinoma of esophagus, carcinoma of the ampulla of vater +3 Alliance for Clinical Trials in Oncology Recruiting No outcome recorded
— NCT07154121 Sep 2025 → Jul 2026 overdue lacrimal duct obstruction Zhongshan Ophthalmic Center, Sun Yat-sen University Recruiting No outcome recorded
— NCT06966440 Jun 2025 → Jun 2028 expected pancreatic adenocarcinoma Ruijin Hospital Recruiting No outcome recorded
— NCT06737406 May 2025 → Jul 2026 overdue common wart Mazandaran University of Medical Sciences Recruiting No outcome recorded
— NCT06893887 May 2025 → Dec 2027 expected hepatocellular carcinoma Nanjing Tianyinshan Hospital Recruiting No outcome recorded
— NCT06894797 Apr 2025 → Oct 2026 expected — Peking University Cancer Hospital & Institute Recruiting No outcome recorded
— NCT06688786 Nov 2024 → Jul 2025 overdue rectal cancer Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Active not recruiting No outcome recorded
— NCT06831981 Sep 2024 → Jun 2036 expected rectal cancer University Hospital Tuebingen Recruiting No outcome recorded
Phase not stated2 trials · 1 met primary
— NCT02436044 — hepatic vascular disorder, hepatocellular carcinoma Ming Zhao Approved for marketing No outcome recorded
— NCT00786058 — malignant pancreatic neoplasm CONKO-Studiengruppe Approved for marketing Met primary
Comparator or background therapy1,334 trials
Phase 0 NCT07821177 Background Sep 2026 → Sep 2027 expected urinary bladder carcinoma, urothelial carcinoma Dana-Farber Cancer Institute Active not recruiting No outcome recorded
Phase 0 NCT07328087 Background Feb 2026 → Dec 2030 expected colorectal cancer Biogenea Pharmaceuticals Ltd. Recruiting No outcome recorded
Phase 0 NCT06011772 Background Dec 2023 → Feb 2026 overdue colorectal cancer Roswell Park Cancer Institute Active not recruiting No outcome recorded
Phase 0 NCT05590117 Comparator Oct 2022 → Oct 2023 colorectal cancer, mucositis, peripheral neuropathy Tanta University Unknown No outcome recorded
Phase 0 NCT05108428 Background Dec 2021 → Oct 2023 overdue rectum adenocarcinoma H. Lee Moffitt Cancer Center and Research Institute Active not recruiting No outcome recorded
Show all 1,334 trials opens the full record — a long page

Press releases naming this drug 23 releases

DateIssuerRelease
2025-11-17 PharmaEngine ONIVYDE® with oxaliplatin, fluorouracil and leucovorin will be included in Taiwan NHI for first-line treatment of metastatic pancreatic adenocarcinoma pharmaengine.com ↗
2021-11-25 Ono Pharmaceutical Co., Ltd. ONO Receives Approval of Opdivo® (nivolumab) for Expanded Use for Two Indications in Japan - First-line Treatment of Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy - Adjuvant Treatment of Esophageal Cancer PDF(192 KB) @media screen and (max-width: 767px){ .mod__table-data { min-width: 100px !important; } } Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) and Bristol-Myers Squibb K.K. (Shinjuku, Tokyo; President, Jean-Christophe Barland) today announced that ONO has received the approvals of Opdivo® (generic name: nivolumab) Intravenous Infusion (“Opdivo”), a human anti-PD-1 monoclonal antibody in Japan, for expanded use for the first-line treatment of unresectable advanced or recurrent gastric cancer in combination with chemotherapy, and adjuvant treatment of esophageal cancer, for a partial change in approved items of the manufacturing and marketing approval. 〈Approval for the first-line treatment of unresectable advanced or recurrent gastric cancer〉 This approval is based on the results from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44): A global multi-center, randomized, open-label Phase 3 clinical study, evaluating Opdivo plus chemotherapy or Opdivo plus Yervoy (ipilimumab) combination compared to chemotherapy alone in patients with previously untreated, non-human epidermal growth factor receptor 2 (non-HER2)-positive, unresectable advanced or recurrent gastric cancer (GC), gastroesophageal junction cancer (GEJC) or esophageal adenocarcinoma (ESA), conducted on a world-wide basis including Japan, South Korea and Taiwan In this study, Opdivo plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival (OS) both in all randomized patient population and OS in PD-L1 positive patients with a combined positive score (CPS) ≥5, one of the primary endpoints, versus chemotherapy. Furthermore, Opdivo plus chemotherapy demonstrated a statistically significant extension in progression-free survival (PFS) in PD-L1 positive patients with CPS ≥5, the other primary endpoint, versus chemotherapy. The safety profile of Opdivo plus chemotherapy in the study was consistent with the known safety profiles of the individual treatments. ATTRACTION-4 study (ONO-4538-37): A multi-center, randomized Phase 2/3 clinical study, evaluating Opdivo plus chemotherapy compared to placebo plus chemotherapy in patients with previously untreated, HER-2 negative, unresectable advanced or recurrent GC or GEJC, conducted in Japan, South Korea and Taiwan In this study, Opdivo plus chemotherapy showed a statistically significant extension in PFS, one of the primary endpoints, versus placebo plus chemotherapy. On the other hand, Opdivo plus chemotherapy did not demonstrate a statistically significance in OS, the other of the primary endpoints. The safety profile of Opdivo plus chemotherapy in the study was consistent with the known safety profiles of the individual treatments. About CheckMate -649 study (ONO-4538-44) Checkmate -649 is a multi-center, randomized, open-label Phase 3 clinical study, evaluating Opdivo plus chemotherapy or Opdivo plus Yervoy combination compared to chemotherapy alone in patients with previously untreated, non-HER2-positive, unresectable advanced or recurrent gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma. Patients in the Opdivo plus chemotherapy arm received Opdivo 240 mg plus fluorouracil, calcium folinate and oxaliplatin (FOLFOX) every two weeks or Opdivo 360 mg plus capecitabine and oxaliplatin (CapeOX) every three weeks. Patients in the chemotherapy arm received FOLFOX or CapeOX every two or three weeks, respectively. All patients continued treatment up to two years or until disease progression, unacceptable toxicity or withdrawal of consent. The primary endpoints of the study are overall survival (OS) in PD-L1 positive patients with a combined positive score (CPS) ≥ 5 treated with Opdivo plus chemotherapy and progression-free survival (PFS) in CPS ≥ 5 patients treated with Opdivo plus chemotherapy. Key secondary endpoint is OS in CPS ≥ 1 and all-randomized patients treated with Opdivo plus chemotherapy. About ATTRACTION-4 study (ONO-4538-37) ATTRACTION-4 study is a multi-center, randomized Phase 2/3 clinical study, evaluating Opdivo plus chemotherapy (oxaliplatin + S-1 or capecitabine) compared to placebo plus chemotherapy in patients with previously untreated, HER2 negative unresectable advanced or recurrent gastric cancer or gastroesophageal junction cancer. Patients received Opdivo 360 mg or placebo every 3 weeks until disease progression or unacceptable toxicity is observed. The primary endpoints of the study are progression-free survival (PFS) and overall survival (OS). About Gastric cancer It is estimated that about 138,000 new cases 1) are diagnosed with gastric cancer per year in Japan (about 1,089,000 cases worldwide 2) ) and approximately 46,000 deaths 1) (about 768,000 worldwide 2) ) per year resulting from this disease 1) , which is the 2nd most common type of cancer after lung cancer in Japan. As there has been little progression in the standard of care of first-line chemotherapy for the HER2 negative unresectable, advanced or recurrent gastric cancer in the past decade in Japan, an innovative treatment option is needed in this patient population. Globocan 2020: Stomach Cancer, Japan, World Health Organization https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf Globocan 2020: Stomach Cancer, World, World Health Organization https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf 〈Approval for the adjuvant treatment of esophageal cancer〉 This approval is based on the results from a global multi-center, randomized, double-blind Phase 3 clinical study, CheckMate -577 study (ONO-4538-43), evaluating Opdivo monotherapy as an adjuvant treatment in patients with resected esophageal cancer (ESC) or gastroesophageal junction cancer (GEJC) compared to placebo. In this study, Opdivo showed a statistically significant improvement in disease-free survival (DFS), the primary endpoint of the study, compared to placebo. The safety profile of Opdivo in this study was consistent with previously reported studies of Opdivo monotherapy. About CheckMate -577 study (ONO-4538-43) CheckMate -577 study is a global multi-center, randomized, double-blind Phase 3 clinical study, evaluating Opdivo monotherapy as an adjuvant treatment in patients with resected esophageal cancer or gastroesophageal junction cancer (GEJC) who have received chemoradiation therapy (CRT) and have not achieved a pathological complete response. Following neoadjuvant CRT and complete tumor surgical resection (also known as trimodality therapy), patients were randomized to receive Opdivo or placebo. In patients receiving Opdivo, it was administered at 240 mg every two weeks for 16 weeks followed by Opdivo 480 mg every four weeks until disease recurrence, unacceptable toxicity or withdrawal of consent, with a maximum of one year total treatment duration. The primary endpoint of the study is disease-free survival (DFS) and the secondary endpoint is overall survival (OS). About esophageal cancer Esophageal cancer is a malignant tumor that occurs in the inner layer (mucosa) of the esophagus and grows outside (toward the deeper layer). There are two main histological types of esophageal cancer; squamous cell carcinoma (SCC) and adenocarcinoma. SCC is the predominant type accounting for about 90% of all esophageal cancer in Japan. It is estimated that about 26,000 new cases1) are diagnosed with esophageal cancer per year in Japan (about 604,000 cases worldwide 2) ) and approximately 12,000 deaths 1) (about 544,000 worldwide 2) ) per year resulting from this disease. In Japan, radical resection following neoadjuvant therapy is performed as a treatment for resectable locally advanced esophageal cancer that does not have distant metastasis, but recurrence has been observed in 28-47% after radical resection. Furthermore, since the prognosis of recurrent cases after radical resection of esophageal cancer is extremely poor 3) , it is considered that there is a high medical need for postoperative adjuvant therapy aimed at suppressing recurrence. Globocan 2020: Esophageal Cancer, Japan, World Health Organization Available at: https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf Globocan 2020: Esophageal Cancer, World, World Health Organization Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf Guideline for Diagnosis and Treatment of Carcinoma of the Esophagus 2017, The Japan Esophageal Society Overview of Opdivo® Intravenous Infusion Product name Opdivo® Intravenous Infusion 20mg, 100mg, 120mg and 240mg Generic name (JAN) Nivolumab (Genetical recombination) Indication Melanoma Unresectable, advanced or recurrent non-small cell lung cancer Unresectable or metastatic renal cell carcinoma Recurrent or refractory classical Hodgkin lymphoma Recurrent or metastatic head and neck cancer Unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy Unresectable advanced or recurrent malignant pleural mesothelioma Microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed after chemotherapy Unresectable advanced or recurrent esophageal cancer that has progressed after chemotherapy Adjuvant treatment of esophageal cancer Dosage and administration 〈Melanoma〉 Usually, for adults, administer at 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In the adjuvant treatment of melanoma, the administration period does not exceed 12 months. In combination therapy with ipilimumab for unresectable melanoma, usually, for adults, administer 80 mg of nivolumab every 3 weeks for 4 doses. After that, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. 〈Unresectable, advanced or recurrent non-small cell lung cancer , and unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy 〉 Usually, for adults, administer at 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In combination therapy with other anti-tumor drugs, usually, for adults, administer 240 mg of nivolumab every 2 weeks or 360 mg every 3 weeks as intravenous infusion. 〈Unresectable or metastatic renal cell carcinoma〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In combination with cabozantinib, usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In combination therapy with ipilimumab for unresectable or metastatic renal cell carcinoma previously untreated with chemotherapy, usually, for adults, administer 240 mg of nivolumab as intravenous infusion every 3 weeks for 4 doses. After that, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. 〈Recurrent or refractory classical Hodgkin lymphoma〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. Usually for pediatrics, administer 3 mg/kg (body weight) of nivolumab every 2 weeks as intravenous infusion. For pediatrics weighing 40 kg (body weight) or more, nivolumab can be administered at 240 mg of every 2 weeks or 480 mg every 4 weeks as intravenous infusion. 〈Recurrent or metastatic head and neck cancer〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. 〈Unresectable advanced or recurrent malignant pleural mesothelioma〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In combination therapy with ipilimumab, usually, for adults, administer 240 mg of nivolumab every 2 weeks or 360 mg every 3 weeks as intravenous infusion. 〈Microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed after chemotherapy〉 Usually, for adults, administer at 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In combination therapy with ipilimumab, usually, for adults, administer 240 mg of nivolumab as intravenous infusion every 3 weeks for 4 doses. After that, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. 〈Unresectable advanced or recurrent esophageal cancer that has progressed after chemotherapy, and adjuvant treatment of esophageal cancer〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. In the adjuvant treatment of esophageal cancer, the administration period does not exceed 12 months. 〈 Recurrent or metastatic head and neck cancer, unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy, and unresectable advanced or recurrent esophageal cancer that has progressed after chemotherapy〉 Usually, for adults, administer 240 mg of nivolumab every 2 weeks or 480 mg every 4 weeks as intravenous infusion. Manufacturer/distributor Ono Pharmaceutical Co., Ltd. Co-promotion Bristol-Myers Squibb K.K. Note: Underlined parts show the revised ones according to this approval. About Opdivo Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers since the approval for the treatment of melanoma in Japan in July 2014. Opdivo is currently approved in more than 65 countries, including Japan, South Korea, Taiwan, China, the US and European Union. In Japan, ONO launched Opdivo for the treatment of unresectable melanoma in September 2014. Thereafter, Opdivo received an approval for additional indications of unresectable, advanced or recurrent non-small cell lung cancer in December 2015, unresectable or metastatic renal cell carcinoma in August 2016, relapsed or refractory classical Hodgkin lymphoma in December 2016, recurrent or metastatic head and neck cancer in March 2017, unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy in September 2017, unresectable advanced or recurrent malignant pleural mesothelioma which has progressed after chemotherapy in August 2018, and microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed following chemotherapy and unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy in February 2020. In addition, ONO has submitted supplemental applications for the adjuvant treatment of urothelial cancer and cancer of unknown primary, and is conducting clinical development program including hepatocellular carcinoma, ovarian cancer, bladder cancer, prostate cancer, pancreatic cancer, biliary tract cancer, etc. About the ONO and Bristol-Myers Squibb Collaboration In 2011, through a collaboration agreement with Bristol-Myers Squibb (BMS), ONO granted BMS its territorial rights to develop and commercialize Opdivo globally except in Japan, South Korea and Taiwan, where ONO had retained all rights to Opdivo except the US at the time. In July 2014, ONO and BMS further expanded the companies’ strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies – as single agent and combination regimens – for patients with cancer in Japan, South Korea and Taiwan. Back to List ono-pharma.com ↗
2021-08-12 Xiromed LLC Xiromed LLC Launches Fluorouracil Injection 50mg/mL xiromed.com ↗
2021-06-08 Cardiff Oncology Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer cardiffoncology.com ↗
2020-06-18 Hill Dermaceuticals, Inc. Tolak® (fluorouracil) 4% Cream successfully registered in the United Kingdom and 13 European countries hillderm.com ↗
2019-09-23 Allarity Therapeutics Oncology Venture presents positive data at ESMO on DRP as a response predictor for 5-FU treatment in colorectal cancer allarity.com ↗
2017-03-03 Hill Dermaceuticals, Inc. Pierre Fabre and Hill Dermaceuticals, Inc. announce a strategic commercial partnership for TOLAK® (fluorouracil) Cream 4% in the USA and beyond hillderm.com ↗
2016-10-18 Takeda Shire Granted EU Marketing Authorization of ONIVYDE®, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy takeda.com ↗
2015-12-11 Orphan Australia BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) serb.com ↗
2015-09-10 Orphan Australia BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU) serb.com ↗
2014-09-17 Allarity Therapeutics MPI abstract published on the ESMO homepage shows that the MPI’s genetic response profile can predict efficacy of adjuvant 5-FU in colon cancer allarity.com ↗
2014-09-17 Allarity Therapeutics Forskningsresultater som viser, at MPI’s genetiske responsprofil kan forudsige effekt af adjuverende 5-FU kemoterapi ved tyktarmskræft, er nu offentliggjort som abstract på ESMO’s hjemmeside allarity.com ↗

Evidence & citations 38 cited values

Every value below carries the sentence it was read from. 2,896 sources stand behind the page.

FieldValueCited text
Known as fluorouracil “Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1...” NCT06966440 ↗
1144

“Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 2023

“Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025

“modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a...” PMID 30575490 ↗ Dec 2018

“Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2...” NCT02527772 ↗

“Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗

“Randomization to receive 400 mg sorafenib twice daily (sorafenib group) or 400 mg sorafenib twice daily plus HAIC (SoraHAIC group) (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2,...” PMID 31070690 ↗ Jul 2019

“oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion...” NCT06346197 ↗

“This phase II trial included patients with clinical T1-T3abN0 low- or mid-rectal adenocarcinoma eligible for endoscopic resection who were treated with 3 months of chemotherapy...” PMID 35981270 ↗ Aug 2022

“The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil,...” PMID 32930387 ↗ Oct 2020

“The mFOLFOX regimen was administered via hepatic artery: oxaliplatin , 85mg/m2 , from hour 0 to 2 on day1 ; leucovorin , 400mg/m2 , from hour 2 to 3 on day 1 ; fluorouracil ,...” NCT05007587 ↗

Show 1,134 more sources

Known as 5 fluouracil “5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)” NCT03069950 ↗
1

“continuous 5 fluouracil infusion plus long-acting octreotide” NCT00953394 ↗

Known as 5 FU (Adrucil) “5 FU (Adrucil)” NCT02178709 ↗
Known as 5-flourouracil “the control group (n=28) which received 6 cycles of folinic acid, fluorouracil and irinotecan (FOLFIRI) regimen (5-flourouracil, leucovorin, irinotecan)” PMID 35022282 ↗ Jan 2022
Known as 5-fluorouracil “Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the...” NCT01542931 ↗
1082

“Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗

“Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel...” NCT03306121 ↗

“Definitive chemoradiation involved induction chemotherapy with 5-fluorouracil (5-FU) (650 mg/mg(2)/day), cisplatin (15 mg/mg(2)/day), and paclitaxel (200 mg/mg(2)/day) for two...” PMID 21507583 ↗ Apr 2011

“After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without...” PMID 41837962 ↗ Apr 2026

“Treatment in this multicentric neoadjuvant pilot study consisted of panitumumab (9 mg/kg) for eight cycles q.3 weeks combined with four cycles of 5-fluorouracil, epidoxorubicin...” PMID 24827135 ↗ May 2014

“Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for...” NCT05290116 ↗

“mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes,...” NCT03099265 ↗

“The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5...” NCT04083235 ↗

“The FOLFOXIRI chemotherapy regimen (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) will be administered according to the study protocol as part of total neoadjuvant...” NCT07277842 ↗

“FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin): 4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin...” NCT02452853 ↗

Show 1,072 more sources

Known as 5-Fluorouracil (5-FU) “5-Fluorouracil (5-FU)” NCT00153998 ↗
2

“5 Fluorouracil (5-FU)” NCT02624726 ↗

“5-Fluorouracil (5-FU)” NCT01581307 ↗

Known as 5-Fluorouracil (5-FU; Efudex) “5-Fluorouracil (5-FU; Efudex)” NCT01749956 ↗
Known as 5-fluorouracile “5-fluorouracile (D1) H+3: 400mg/m² IV infusion over 15min” NCT04392479 ↗
5

NCT01858662 ↗

NCT02268695 ↗

NCT02701088 ↗

NCT02640365 ↗

NCT02484677 ↗

Known as 5-fluorouracilo “5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days” NCT00765011 ↗
Known as 5-fluoruracil “5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.” NCT03031444 ↗
13

“Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin)” NCT07000253 ↗

“Oxaliplatin, folinic acid, irinotecan and 5-Fluoruracil will be administered on day 1 and 15 every 28 days” NCT04793932 ↗

“5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)” NCT02613650 ↗

“5-Fluoruracil continuous infusion of 2400 mg/m2 IV over 46h” NCT04452461 ↗

“concurrent capecitabine or 5-fluoruracil (5-FU)” NCT02199236 ↗

NCT00615602 ↗

NCT01985724 ↗

NCT02340949 ↗

NCT00525200 ↗

NCT02879513 ↗

Show 3 more sources

Known as 5-Flurouracil “5-Flurouracil (5-FU), leucovorin, and irinotecan; the combination is known as FOLFIRI.” NCT01183494 ↗
Known as 5-FU “Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗
1121

“Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a...” NCT00548548 ↗

“Two prospective phase II studies evaluated the efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) or the oral prodrug capecitabine reporting an objective...” NCT07844057 ↗

“To assess the safety of intravenous (IV) bolus fluorouracil (5-FU) in combination with standard-of-care radiation therapy and to determine the recommended phase 2 dose (RP2D)...” NCT07848568 ↗

“Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for...” NCT03604965 ↗

“Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment...” NCT03301454 ↗

“It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400...” NCT01124630 ↗

“METHODS AND ANALYSIS: NET-02 is a UK, multicentre, randomised (1:1), parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan...” PMID 32029495 ↗ Feb 2020

“Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1,...” NCT02620423 ↗

“The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5...” NCT04083235 ↗

“The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as...” NCT00037180 ↗

Show 1,111 more sources

Known as 5-FU (5-fluorouracil) “5-FU (5-fluorouracil)” NCT01516216 ↗
Known as Adrucil “Adrucil, fluorouracil” NCT02046538 ↗
1

“Fluorouracil/Adrucil” NCT02741570 ↗

Known as Adrucil, fluorouracil “Adrucil, fluorouracil” NCT02046538 ↗
Known as Carac “Carac® (Fluorouracil) Cream” NCT02616601 ↗
Known as Efudex ClinicalTrials.gov intervention name — accepted as the source's own label NCT00121511 ↗
1

NCT03996252 ↗

Known as Efudex, 5-FU “Efudex, 5-FU” NCT00847912 ↗
Known as Five-Fluorouracil “Five-Fluorouracil (FU) is an antitumor agent blocks DNA synthesis by inhibition of pyrimidine and thymidine.” NCT07041749 ↗
Known as Fluorouracil (5-FU) “Fluorouracil (5-FU)” NCT01571024 ↗
2

“Fluorouracil ; 5-FU” NCT01834963 ↗

“Fluorouracil: 5-Fu” NCT01642771 ↗

Known as Fluorouracil Injection “5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.” NCT04796948 ↗
1

“LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu(Fluorouracil Injection)” NCT04088604 ↗

Known as Fluorouracilo “Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the...” NCT02246127 ↗
Known as Fluouracil “Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m\^2 intravenous (IV) over 5 minutes.” NCT00941655 ↗
Known as flurouracil “The standard chemotherapy arm (Arm 1) will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV...” NCT02624999 ↗
Known as FUra “This protocol will evaluate the activity of 5-Fluorouracil (FUra) given as a 1 hour infusion in combination with leucovorin (LV) and interferon IFN alpha-2a in patients with...” NCT00001428 ↗